hansoh pharma merck news - Search News

Merck signs up to $2 billion deal for oral weight-loss drug

Reuters on MSN · 22h

Merck signs deal worth up to $2 billion with China's Hansoh for oral obesity drug

Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharma to develop and sell the Chinese biotech's experimental oral obesity drug that works similar to the popular weight-loss treatments Wegovy and Zepbound.

Seeking Alpha on MSN · 22h

Merck enters obesity drug race in pact with Chinese pharma Hansoh

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at weight loss and other cardio metabolic conditions.

NBC New York · 22h

Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal

Merck will pay Hansoh $112 million upfront for rights to the drug, with the potential for an additional $1.9 billion in payments and royalties on sales.

FierceBiotech23h

Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for a ...

23h

Merck and Hansoh Pharma sign exclusive global license agreement for HS-10535

Merck (MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, announced that they have entered into an exclusive global license agreement ...

21h

What's Going On With Merck Shares Wednesday?

Merck & Company Inc (NYSE:MRK) shares are trading higher. The company on Wednesday announced a GLP-1 agreement with Chinese ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results